bendamustine

基本解釋

Objective: To synthesize bendamustine.
目的:合成鹽酸苯達(dá)莫司汀。
Background : Bendamustine, a bifunctional alkylating agent with anticipated purin-like properties is active in metastatic breast cancer (MBC) patients.
苯達(dá)莫司汀，具有烷化劑和嘌呤類似的雙相功能可以在轉(zhuǎn)移性乳腺癌（MBC）患者中發(fā)揮作用。
Results: The structure of the target compound was confirmed by MS,1H-NMR,IR analysis.The total yield of bendamustine was 33.5%.
結(jié)果:目標(biāo)化合物的質(zhì)譜、核磁共振氫譜、紅外光譜均與文獻(xiàn)報(bào)道相吻合;總收率為33.;5%25。
This multicenter phase II trial defines the toxicity and activity of bendamustine in heavily pretreated patients.Patients and methods: Fifty-one patients were included.
本實(shí)驗(yàn)為多中心II期臨床試驗(yàn)，旨在定義苯達(dá)莫司汀在治療失敗乳腺癌患者中的毒性和治療效應(yīng)。
Conclusion : Single-agent bendamustine is an active treatment in patients with MBC independent of the previous treatment.The low toxicity profile favors its use as a single agent.
苯達(dá)莫司汀單藥治療MBC具有療效，而其低毒性的特性支持其采用單藥治療。